
Can Gearhead Kuniskis and the Return of SRT Bring Much-Needed Cred, Fix What Ails Stellantis?
Tim Kuniskis, known for his passion for cars, has been promoted to lead Stellantis in North America, focusing on revitalizing the product lineup. CEO Antonio Filosa aims to regain U.S. market trust. Kuniskis's expertise is expected to strengthen consumer focus and ease Filosa's workload.
This summary was generated by AI using content from this MotorTrend article Read Next
Tim Kuniskis, the current CEO of the Ram brand, has been appointed head of American brands and North America marketing and retail strategy. It is a new position, reporting to Filosa. Kuniskis will continue to run Ram, and will add the resurrected Street and Racing Technology (SRT) division to his duties to provide high-performance engineering across all the brands. "We're getting the band back together," Kuniskis said.
Filosa took over as Stellantis CEO on June 23 and announced a 13-member leadership team with little change. The former North America chief operating officer said he would continue to oversee the region and the Chrysler, Jeep, Dodge, and Ram brands. But that put a lot on the new global CEO's plate. The promotion of Kuniskis will help ease his burden.
The Story of Tim Kuniskis
Kuniskis has a reputation as a car geek, especially attuned to muscle cars and powerful trucks. The native of Rochester, New York, has shown an ability to understand what customers want from each brand and fight to get those models into production. The job seems tailored to his strengths as a product cheerleader. He will work across the brands to connect with dealers and customers. "Connecting with our customers, delivering the products and experiences they want, is critical to reaching our full potential," said Filosa. "Tim has proven time and time again that he is masterful at building brands that reach the heart and soul of the customer. We will leverage his energy, his strategic mindset and his competitive spirit to supercharge all our brand activities."
Kuniskis joined the company in 1992 as a trainee, spent his early years in sales, service, and parts, and working with dealers before getting into marketing, fleet operations, and then brand management. Kuniskis has, over the course of his career, been assigned to all the brands offered in North America. Dodge was a natural fit for the amped up executive and likely closest to his heart. His stint with Alfa Romeo and Maserati seemed the most ill-fitting suit. Ram and Jeep, given their importance and volume, were among the more demanding divisions to run.
Kuniskis retired from Stellantis on June 1, 2024, only to return six months later after the resignation of Tavares to take over Ram once again. Among his first moves: bringing back the Hemi V-8 engine as an option in the 2026 Ram 1500 and announcing plans to enter the NASCAR Truck Series in 2026.
We had a sense Kuniskis was lured back to do more than just resume his old Ram brand job. In January, when Stellantis was looking for a new CEO, MotorTrend asked Kuniskis if he was interested in the top job. 'No. No. Not a snowball's chance in hell,' he said. 'No way. First, not smart enough. Second, zero interest. I love product, not politics. Life is so much easier when you understand who you are and what you like and what your limitations are. I started out as a dealership mechanic. I went from a mechanic to the sales department to working as a sales rep for this company and now I have this job. I have gone way beyond my IQ. I like this job. I screwed up leaving last time. I just needed a vacation. I didn't need to retire.'
So, while Kuniskis is not taking the top job, it appears this particular position piqued his interest.
Filosa's Focus on North America
Given the importance of the U.S., Filosa will continue to be based in Auburn Hills. His predecessor Carlos Tavares made Europe his home base and by the end of his tenure, there was a strong sense he did not prioritize or have much respect for North American operations. The last CEO with a U.S. address was Sergio Marchionne, who died in 2018.
While most applauded the move to name Filosa as the new CEO, Wall Street was not impressed that most top executives stayed in their current roles. One of the few executives leaving the company was chief planning officer Beatrice Foucher. In the U.S., the brand chiefs kept their current roles.
Dealers are happy with Filosa at the helm and his promises to give them the attention they seek to restore sales and profitability. That includes a robust product portfolio, an area that will now fall to Kuniskis to help orchestrate.
Strong Team With Lots of History
Kuniskis will work with a team of brand managers with experience that dates back to former Chrysler regimes. Bob Broderdorf has led every brand over his decades-long career and is now head of Jeep. Matt McAlear, who was Kuniskis's sidekick at Dodge for years, now leads the muscle-car brand. Chris Feuell has been mostly associated with the Chrysler brand but handled Ram briefly and added Alfa Romeo to her duties.
Ned Curic continues as head of product development and technology. Other long-timers: Ralph Gilles remains head of design and Olivier Francois is still head of marketing.
Stellantis lost market share in the U.S. in 2024 with a product lineup with key gaps, and pricing considered too high to be competitive. Consumers, dealers, suppliers, and employees were unhappy in the final stages of the Tavares regime. Filosa is working to regain trust with all these stakeholders. He will rely on Kuniskis to help get it right.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
BrightSpring's Onco360 Becomes National Pharmacy Partner for New Cancer, Rare Disease Therapies
BrightSpring Health Services Inc. (NASDAQ:BTSG) is one of the best new stocks to buy now. On June 18, BrightSpring Health Services announced that its specialty pharmacy, called Onco360, has been chosen as the national pharmacy partner for several newly approved therapies. These innovative treatments target advanced cancers and rare genetic disorders. BrightSpring delivers care and clinical solutions to 400,000+ customers, clients, and patients daily across all 50 states. Onco360 will provide access, education, data, and expert support for patients suffering from advanced ovarian and lung cancers, as well as neurofibromatosis type 1. A medical technician using surgical robotics to perform minimally-invasive urologic surgery in an operating room. Onco360 has been selected as a pharmacy partner for the following specific medication therapies: GOMEKLI, which is approved for adult and pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas/PN not suitable for complete resection; AVMAPKI FAKZYNJA CO-PACK, which is approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer/LGSOC who have received prior systemic therapy; and IBTROZI, which is approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). BrightSpring Health Services Inc. (NASDAQ:BTSG) is a home and community-based healthcare services platform in the US that operates through 2 segments: Pharmacy Solutions and Provider Services. Onco360 is a national, independent Oncology Pharmacy and clinical support services company. While we acknowledge the potential of BTSG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Waystar Study Highlights AI's Critical Role, Proven ROI in Healthcare Payments
Waystar Holding Corp. (NASDAQ:WAY) is one of the best new stocks to buy now. On June 23, Waystar announced the findings of a commissioned study conducted by Forrester Consulting. The study is titled 'AI in Healthcare Payments Software: A Strategic Imperative,' and revealed that AI is becoming increasingly critical in revenue cycle management/RCM due to its proven impact and measurable ROI. The research shows acceleration in AI adoption within healthcare. 82% of healthcare leaders now consider AI an integral part of their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering improvements in key revenue cycle metrics, such as a 13% to 37% improvement in high-impact areas such as claim accuracy, denial prevention, workforce efficiency, and payment speed. A medical professional with a patient explaining the effects of neurostimulation treatments. Trust in AI is growing, with 60% of decision-makers reporting increased confidence since implementing AI. ~ 70% of healthcare leaders view AI as a high or critical organizational priority, and 60% plan to increase their AI investment. The study is based on responses from 300+ healthcare leaders and highlights a preference for existing RCM software partners when it comes to AI capabilities. Waystar serves ~30,000 clients and represents over 1 million distinct providers, including 16 of the top 20 institutions on the US News Best Hospitals list. Waystar Holding Corp. (NASDAQ:WAY) develops a cloud-based software solution for healthcare payments. While we acknowledge the potential of WAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Solventum Amends Thermo Fisher Deal, Retains Water Filtration Business
Solventum Corporation (NYSE:SOLV) is one of the best new stocks to buy now. On June 25, Solventum announced an amendment to its transaction agreement with Thermo Fisher Scientific Inc. (NYSE:TMO). The revised agreement now excludes Solventum's drinking water filtration business from the assets being acquired by Thermo Fisher. Consequently, the cash consideration for the acquisition has been adjusted from ~$4.1 billion to $4 billion. The net proceeds from this sale are intended for debt reduction. This amendment is expected to streamline the transaction and accelerate its closure, which is still expected by the end of this year. Under the new terms, Thermo Fisher will be entitled to a payment of up to $75 million from Solventum. Keeping the Water Business is projected to increase Solventum's annual EPS gain by $0.15 to $0.2. A healthcare professional wearing a health communications device discussing patient data with a colleague. The terms of the amended agreement remain largely consistent with the initial agreement, with modifications specifically reflecting the exclusion of the Water Business. These adjustments include changes to non-compete clauses and related provisions, as well as certain reverse services, manufacturing, and supply agreements that will now support the retained Water Business. Solventum Corporation (NYSE:SOLV) is a healthcare company that develops, manufactures, and commercializes a portfolio of solutions to address customer and patient needs internationally. Thermo Fisher Scientific Inc. (NYSE:TMO) provides life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services internationally. While we acknowledge the potential of SOLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio